Stock Financial Ratios

HTH / Hilltop Holdings, Inc. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Price25.48
Volume504,400.00
Market Cap ($M)2,472.77
Enterprise Value ($M)0.00
Book Value ($M)1,912.08
Book Value / Share19.64
Price / Book1.29
NCAV ($M)-11,450.98
NCAV / Share-117.62
Price / NCAV-0.22
Income Statement (mra) ($M)
Revenue0.00
EBITDA0.00
Net Income133.14
Balance Sheet (mrq) ($M)
Cash & Equivalents0.00
Cash / Share0.00
Assets0.00
Liabilities0.00
Quick Ratio
Current Ratio
Management Effectiveness (mra)
Return on Invested Capital (ROIC)0.06
Return on Assets (ROA)0.01
Return on Equity (ROE)0.07
Identifiers and Descriptors
CUSIP432748101
Central Index Key (CIK)1265131
Industry Groups
SIC 6022 - State Commercial Banks
Other Related CUSIPS
432748951
432748901
Share Statistics
Common Shares Outstanding95,987,840
Weighted Average Number Of Diluted Shares Outstanding97,353,000
Weighted Average Number Diluted Shares Outstanding Adjustment216,000
Common Stock Shares Outstanding95,982,184
Weighted Average Number Of Shares Outstanding Basic97,137,000
Scoring Models
Piotroski F-Score4.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Kaplan-Zingales KZ-IndexN/A
Cash Conversion CycleN/A
Per Share Metrics
Assets Other Non Current Per Share0.00
Intangibles Per Share0.00
Goodwill Per Share0.00
Accumulated Depreciation And Depletion Per Share0.00
Equity Per Share0.00
Liabilities Current Per Share0.00
Minority Interest Per Share0.00
Deferred Income Tax Liabilities Per Share0.00
Current Portion Of Long Term Debt Per Share0.00
Property Plant And Equipment Gross Per Share0.00
Accounts Receivable Per Share0.00
Property Plant And Equipment Per Share0.00
Inventory Raw Materials Per Share0.00
Liabilities Per Share0.00
Cash And Equivalents Per Share0.00
Assets Other Current Per Share0.00
Cash Per Share0.00
Inventory Finished Goods Per Share0.00
Accounts Payable Per Share0.00
Liabilities Other Non Current Per Share0.00
Preferred Stock Value Outstanding Per Share0.00
Assets Non Current Per Share0.00
Inventory Per Share0.00
Retained Earnings Per Share0.00
Liabilities And Stock Equity Per Share0.00
Assets Current Per Share0.00
Inventory Work In Progress Per Share0.00
Property Plant And Equipment Net Per Share0.00
Additional Paid In Capital Per Share0.00
Long Term Debt Per Share0.00
Treasury Stock Per Share0.00
Debt Per Share0.00
Assets Per Share0.00

Related News Stories

Hilltop Holdings (HTH) Agrees to Buy The Bank of River Oaks

2018-02-14 zacks
Hilltop Holdings Inc. (HTH - Free Report) has agreed to acquire The Bank of River Oaks, with an aim to further expand operations. The cash transaction is expected to be completed by third-quarter 2018, subject to shareholder and regulatory approval. Per the deal, Hilltop Holdings will pay a total of $85 million in cash to the shareholders and option holders of The Bank of River Oaks. With this acquisition, Hilltop Holdings will be in a position to further expand its banking operations in the Houston area, where The Bank of River Oaks operates three full-service branches. (39-0)

BRIEF-Hilltop Holdings Inc. To Acquire The Bank Of River Oaks

2018-02-13 reuters
* HILLTOP HOLDINGS INC - AGREED TO PAY CASH IN AGGREGATE AMOUNT OF $85 MILLION TO SHAREHOLDERS AND OPTION HOLDERS OF BANK OF RIVER OAKS.​ (1-0)

Telecom Stocks Earnings Roster for Jan 30: HRS, GLW & JNPR

2018-01-29 zacks
The earnings season has already started and the picture, so far, appears to be encouraging. Per the Earnings Preview dated Jan 26, nearly 133 of the S&P 500 members have reported their results. Out of these companies, approximately 81.2% delivered positive earnings surprises, while 78.9% surpassed top-line expectations. (110-0)

Novartis' Lutathera Gets FDA Approval for Pancreatic Tumors

2018-01-29 zacks
Novartis AG’s (NVS - Free Report) subsidiary, Advanced Accelerator Applications, obtained FDA approval for its new drug application (NDA) for Lutathera (lutetium Lu 177 dotatate) for the treatment of somatostatin receptor positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs), including foregut, midgut and hindgut neuroendocrine tumors in adults. (155-1)

CUSIP: 432748101